News
-
-
-
-
PRESS RELEASE
Catheter Precision, Inc. Announces the Presentation of the First Clinical Data on LockeT
Catheter Precision, Inc. announces LockeT study data presentation at Western AFib Symposium. CEO highlights safety, effectiveness, cost savings, and same-day discharge benefits. Event features renowned experts in atrial fibrillation field -
PRESS RELEASE
Catheter Precision, Inc. Participates in AF Symposium
Catheter Precision, Inc. to showcase VIVO 3D imaging system and LockeT suture retention device at AF Symposium Boston. Participating alongside major medical device companies including Medtronic, Boston Scientific, Abbott, and Johnson and Johnson. CEO David Jenkins highlights the opportunity to generate leads and interest from a dedicated audience of electrophysiologists -
PRESS RELEASE
Catheter Precision, Inc. (VTAK) Secures New Distributor for VIVO in Turkey
Catheter Precision, Inc. (NYSE American: VTAK) has signed a new distributor for Turkey for its non-invasive 3D localization system, VIVO, expanding its footprint in Eastern Europe. The company's focus on expanding sales territory and utilizing local personnel familiar with regulations helps streamline the approval process. VIVO, a non-invasive 3D imaging system, enables physicians to identify the origin of ventricular arrhythmias pre-procedure, reducing procedure time. For more information on the company and its products, visit www.catheterprecision.com. -
PRESS RELEASE
Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Sequire Investor Summit in Puerto Rico
Catheter Precision, Inc. (NYSE American: VTAK) announces its participation in the Sequire Investor Summit 2024, showcasing its commitment to advancing the well-being of patients with cardiac arrhythmias. The summit, set to take place on January 23-25, 2024, in San Juan, Puerto Rico, offers a platform for the exchange of opportunities among funds, companies, and investors. With Puerto Rico's favorable tax benefits attracting financial entities and affluent individuals, this event holds promise for impactful discussions and collaborations. For details and registration, visit the official event website. Don't miss Catheter Precision's presentation on February 24 at 3:00 PM. -
PRESS RELEASE
Catheter Precision’s VIVO System Featured in Electrophysiology Publication
Catheter Precision, Inc., a leader in non-invasive 3D mapping for ventricular arrhythmias, announced that their VIVO System was highlighted in a case study by EP Lab Digest, a publication dedicated to electrophysiology. The VIVO System, a non-invasive 3D imaging system, enables physicians to identify the origin of ventricular arrhythmias pre-procedure, streamlining workflow and reducing procedure time. This recognition signifies the value of the work presented and the unique approach taken in the case study. -
PRESS RELEASE
CORRECTION: Catheter Precision, Inc.'s (VTAK) Board Authorizes its CEO and Chairman to Make "Open Market" Purchases of Company Shares
Catheter Precision, Inc. announces that its CEO and Chairman, Mr. David Jenkins, has been authorized to purchase up to 500,000 shares of the Company's common stock in open market transactions. Mr. Jenkins expresses his commitment to the Company and its innovative technology for electrophysiology procedures to improve the treatment of cardiac arrhythmias. The Company continues its focus on developing groundbreaking technology and seeking innovations to improve the overall health of patients with cardiac arrhythmias. -
PRESS RELEASE
Cather Precision, Inc.'s (VTAK) Board Authorizes its CEO and Chairman to Make "Open Market" Purchases of Company Shares
Catheter Precision, Inc., a US-based medical device company, announces that its CEO and Chairman, Mr. David Jenkins, has been authorized to purchase up to 500,000 shares of the Company's common stock. Mr. Jenkins expresses confidence in the Company's future and its innovative technology for electrophysiology procedures to improve the treatment of cardiac arrhythmias. The press release highlights the Company's focus on developing groundbreaking technology and its achievements with the FDA-registered LockeT product and VIVO 3D mapping system. The press release also contains a cautionary note regarding forward-looking statements and contact information for media inquiries.